Immunitybio Inc (IBRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunitybio Inc (IBRX) has a cash flow conversion efficiency ratio of 1.356x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.91 Million) by net assets ($-50.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunitybio Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Immunitybio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Immunitybio Inc total liabilities for a breakdown of total debt and financial obligations.
Immunitybio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunitybio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sulzer AG
SW:SUN
|
0.070x |
|
MRF Limited
NSE:MRF
|
0.096x |
|
Chord Energy Corp
NASDAQ:CHRD
|
0.070x |
|
Hyundai Motor Co Pref
KO:005387
|
-0.039x |
|
Kuala Lumpur Kepong Bhd
KLSE:2445
|
0.030x |
|
Essent Group Ltd
NYSE:ESNT
|
0.038x |
|
SIAM CEMENT UNSP.ADS/1
F:TCM
|
N/A |
|
Matador Resources Company
NYSE:MTDR
|
0.123x |
Annual Cash Flow Conversion Efficiency for Immunitybio Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Immunitybio Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see IBRX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-488.13 Million | $-391.24 Million | 0.802x | +28.05% |
| 2023-12-31 | $-585.94 Million | $-366.76 Million | 0.626x | -16.58% |
| 2022-12-31 | $-449.82 Million | $-337.51 Million | 0.750x | -33.31% |
| 2021-12-31 | $-243.91 Million | $-274.42 Million | 1.125x | -22.37% |
| 2020-12-31 | $-118.49 Million | $-171.72 Million | 1.449x | +214.98% |
| 2019-12-31 | $120.68 Million | $-152.11 Million | -1.260x | -190.36% |
| 2018-12-31 | $146.01 Million | $-63.38 Million | -0.434x | -94.75% |
| 2017-12-31 | $218.84 Million | $-48.78 Million | -0.223x | -69.47% |
| 2016-12-31 | $293.42 Million | $-38.59 Million | -0.132x | -85.04% |
| 2015-12-31 | $356.00 Million | $-25.30 Million | -0.071x | +22.43% |
| 2014-12-31 | $58.42 Million | $-5.35 Million | -0.092x | -139.72% |
| 2013-12-31 | $-2.90 Million | $-668.00K | 0.231x | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more